Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B Korayem, Ali F Altebainawi, Abdulrahman Alshaya, Majed Nahari, Khuzama Alsamnan, Munirah A Alkathiri, Bodoor S Al-Dosari, Abeer A Alenazi, Samiah Alsohimi, Lina I Alnajjar, Mashael Alfaifi, Nora AlQussair, Reem M Alanazi, Munirah F Alhmoud, Nadin L Alanazi, Hadeel Alkofide, Aljawharah M Alenezi, Ramesh Vishwakarma
BACKGROUNDS: Ketamine possesses analgesia, anti-inflammation, anticonvulsant, and neuroprotection properties. However, the evidence that supports its use in mechanically ventilated critically ill patients with COVID-19 is insufficient. The study's goal was to assess ketamine's effectiveness and safety in critically ill, mechanically ventilated (MV) patients with COVID-19. METHODS: Adult critically ill patients with COVID-19 were included in a multicenter retrospective-prospective cohort study...
May 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society